文献速递妇科肿瘤

恶性成人卵巢生殖细胞肿瘤:国际多中心研究识别IC期及以上患者的预后风险因素

Malignant Adult Ovarian Germ Cell Tumors: An International Multicenter Study to Identify Relevant Prognostic Risk Factors for Stage IC and Beyond.
PubMed 文献 · J Clin Oncol · 2026-05-06

该国际多中心研究分析了254例FIGO IC-IV期恶性卵巢生殖细胞肿瘤患者,中位年龄27岁。十年无进展生存率和癌症特异性生存率分别为82.8%和83.2%。多因素分析显示年龄≥35岁、III/IV期及非无性细胞瘤组织学是癌症特异性生存的不良预后因素,而2/3级未成熟畸胎瘤的生存与无性细胞瘤相似。

要点

  • 年龄≥35岁、III/IV期和非无性细胞瘤组织学是独立不良预后因素。
  • IV期患者十年癌症特异性生存率可达79.4%。
  • 高剂量化疗可能改善首次复发生存,但对二次复发无效。

核心结论

  • 晚期(III/IV期)、年龄>35岁和非无性细胞瘤(除外2/3级未成熟畸胎瘤)是不良预后因素。
  • IV期疾病可获得约80%的长期生存率。
  • 高剂量化疗改善首次复发生存,但不改善二次复发生存。

研究设计与样本

  • 国际多中心回顾性研究,纳入254例1971至2018年间在英国两个中心和意大利多中心卵巢癌试验中心接受手术和化疗的FIGO IC-IV期恶性卵巢生殖细胞肿瘤患者。

主要发现

  • 中位年龄27岁(IQR 21-31)。
  • 初始治疗为手术者占87.8%(50.4%保留生育功能,37.4%不保留),或新辅助化疗。
  • 一线治疗后完全缓解84.6%(n=215),部分缓解或疾病稳定7.9%(n=20),进展4.7%(n=12)。
  • 37例(14.6%)死于疾病。
  • 十年无进展生存率82.8%(95% CI 77.2-87.2),癌症特异性生存率83.2%(95% CI 77.3-87.7);IV期癌症特异性生存率79.4%(95% CI 69.5-86.4)。

关键数值与推荐

  • 2/3级未成熟畸胎瘤的癌症特异性生存与无性细胞瘤相似。
  • 32.5%的患者在复发时接受高剂量化疗。

临床怎么用

  • 对年龄≥35岁、III/IV期或非无性细胞瘤组织学的患者应加强预后评估和密切随访。
  • IV期患者仍有较高长期生存机会,应积极治疗。
  • 首次复发可考虑高剂量化疗,二次复发则不推荐。

局限性

  • 回顾性研究设计,跨1971至2018年,治疗方案可能存在异质性。
  • 样本量有限(254例),罕见组织学亚组分析效能不足。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Malignant ovarian germ cell tumors (MOGCTs) are rare, aggressive malignancies predominantly affecting young women. Unlike testicular germ cell tumors, prognostic factors are poorly understood, with small studies suggesting advanced stage as an adverse factor. Here, we examine a large international series to identify relevant prognostic factors. METHODS: We analyzed data from 254 patients with International Federation of Gynecology and Obstetrics stage IC-IV MOGCT, requiring surgery and chemotherapy between 1971 and 2018 at two UK and the Multicenter Italian Trials in Ovarian Cancer centers. RESULTS: The median age was 27 years (IQR, 21-31). Initial treatment was surgery in 87.8% of patients (50.4% fertility sparing, 37.4% nonsparing) or neoadjuvant chemotherapy. Most underwent BEP or POMB/ACE chemotherapy, with 32.5% receiving high-dose chemotherapy (HDCT) at relapse. First-line treatment resulted in a complete response in 84.6% (n = 215) and partial response or stable disease in 7.9% (n = 20), while 4.7% (n = 12) progressed. Overall, 37 patients (14.6%) died of disease. Ten-year progression-free survival and cancer-specific survival (CSS) was 82.8% (95% CI, 77.2 to 87.2) and 83.2% (95% CI, 77.3 to 87.7), respectively. CSS for stage IV disease was 79.4% (95% CI, 69.5 to 86.4). Age ≥35 years (hazard ratio [HR], 2.8 [95% CI, 1.5 to 5.4]; P = .003), stage III/IV disease (HR, 1.4 [95% CI, 1,0.2 to 1.9]; P = .035), and nondysgerminoma histology (HR, 7.3 [95% CI, 1.9 to 64.8]; P = .01) had worse CSS on multivariable analysis. By contrast, CSS of immature grade 2/3 MOGCT mirrored dysgerminomas. HDCT appeared to improve survival in first but not later relapses. CONCLUSION: Advanced stage (III/IV), age >35 years, and nondysgerminoma (excluding grade 2/3 immature teratomas) are adverse prognostic factors. Stage IV disease can achieve 80% long-term survival rates, and HDCT improves survival in first but not second relapse.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Bergamini A, Suyanto S, Savva C, et al. Malignant Adult Ovarian Germ Cell Tumors: An International Multicenter Study to Identify Relevant Prognostic Risk Factors for Stage IC and Beyond. J Clin Oncol. 2026. PMID: 42090637. doi:10.1200/JCO-25-00840

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。